Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A case report: clinically benign anti-Cs(a).

T Sererat1, J Alexander, J Beatty

  • 1American Red Cross Blood Services, Northwest Ohio Region, 2275 Collingwood Blvd., Toledo, OH 43620, USA.

Immunohematology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cissampelos sympodialis Eichl. leaf extract increases the production of IL-10 by concanavalin-A-treated BALB/c spleen cells.

Journal of ethnopharmacology·2000
Same author

Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling.

Journal of immunology (Baltimore, Md. : 1950)·1999
Same author

Gata5 is required for the development of the heart and endoderm in zebrafish.

Genes & development·1999
Same author

Psychiatric comorbidity associated with DSM-IV ADHD in a nonreferred sample of twins.

Journal of the American Academy of Child and Adolescent Psychiatry·1999
Same author

casanova plays an early and essential role in endoderm formation in zebrafish.

Developmental biology·1999
Same author

A molecular pathway leading to endoderm formation in zebrafish.

Current biology : CB·1999
Same journal

Investigation of a neonate with blocked D phenomenon: resolving D type using serologic and molecular methods.

Immunohematology·2026
Same journal

Novel <i>JK*01</i> allele with c.299C>T p.(Thr100Ile) single nucleotide variant associated with loss of Jk<sup>a</sup> expression in two African American donors.

Immunohematology·2026
Same journal

An update on the GE (Gerbich) blood group system.

Immunohematology·2026
Same journal

Effect of long-term frozen storage on antibodies in blood samples: immunoglobulin, tetanus toxin antibody, and ABO antibody.

Immunohematology·2026
Same journal

To contributors to the 2025 issues.

Immunohematology·2026
Same journal

The Indian (IN 023) blood group system: an update.

Immunohematology·2026
See all related articles

This study found no hemolytic transfusion reactions in a patient with anti-Csa and anti-Fya antibodies. Transfusing incompatible red blood cells showed no adverse clinical, serological, or biochemical effects.

Area of Science:

  • Transfusion Medicine
  • Immunology
  • Hematology

Background:

  • Conflicting data exists regarding the clinical significance of anti-Csa (Cost-Stirling) antibodies.
  • The presence of multiple antibodies, such as anti-Csa and anti-Fya, can complicate transfusion management.

Purpose of the Study:

  • To investigate the clinical significance of anti-Csa and anti-Fya antibodies in a patient.
  • To evaluate the outcome of transfusing crossmatch-incompatible red blood cells in this patient.

Main Methods:

  • Serological testing to identify red blood cell antibodies.
  • Transfusion of ABO and Rh-matched, Fya-negative red cells.
  • Monitoring for clinical, serological, and biochemical signs of hemolytic transfusion reactions over an 8-month period.

Related Experiment Videos

Main Results:

  • The patient possessed both anti-Csa and anti-Fya antibodies.
  • Nineteen units of Fya-negative red cells, incompatible by crossmatch, were transfused.
  • No evidence of hemolytic transfusion reactions was observed.

Conclusions:

  • Transfusion of Fya-negative red cells was safe in this patient with anti-Csa and anti-Fya.
  • The clinical significance of anti-Csa may be less critical than previously reported, especially in the context of other antibodies.